Lotus Pharmaceuticals Co (美時化學製藥) yesterday gave an upbeat outlook for global sales of its generic drugs this quarter, as its marketing network now covers more than 130 countries.
Third-quarter sales grew 24.5 percent from a year earlier to NT$1.96 billion (US$64.21 million), mainly boosted by robust US sales of its buprenorphine/naloxone tablets, which are sold under the name Desud Plus, for the treatment of narcotic addiction, the generic drugmaker said.
The company’s sales of lenalidomide for treatment of blood cancer also advanced in Europe, while sales of other drugs in other regions — including Southeast Asia and Africa — also reported rapid growth, Lotus acting spokeswoman Nadiya Chen (陳荻雅) told the Taipei Times by telephone.
International sales used to account for only a single-digit percent of its total sales, but they had risen to about 21 percent as of the end of September, Chen said.
The company expects its international sales to continue growing as it has a chance of having its Desud Plus included in US public health insurance plans after the US government last month said it would include more generic drugs.
Desud Plus is currently only covered by private health insurance plans in the US, as all narcotic addiction treatment drugs included in the public plans are branded medicines, it said.
The company said it hopes to see Desud Plus secure a higher market share in the US next year.
It is also working on gradually enhancing its marketing programs for lenalidomide in South Africa and east Europe, where it faces fewer competitors, as well as promoting gefitinib for lung cancer treatment and vinorelbine for breast cancer treatment in Europe.
Compared with the Europe and the US, the company’s overall sales of generic drugs in Asia have remained comparatively flat in the past few years due to intense competition, Chen said.
To spur new growth, the company next year plans to introduce two new drugs — the anti-obesity drug Qsymia in South Korea and a drug for osteoporosis treatment in Southeast Asia, Chen said.
For the first nine months of this year, the company’s cumulative revenue rose 28.4 percent annually to NT$6.04 billion, with gross margin improving mildly from 48 percent to 50 percent.
Cumulative net profit over the nine-month period totaled NT$523 million, increasing 18 times from a year earlier.
Earnings per share hit a new record of NT$2.17, compared with NT$0.11 a year earlier, company data showed.
The company, which at the end of last month received approval to move from the smaller Taipei Exchange to the main Taiwan Stock Exchange, has no plans to raise new capital for the time being, Chen said.
The share price was not ideal, she added.
Taiwan’s foreign exchange reserves hit a record high at the end of last month, surpassing the US$600 billion mark for the first time, the central bank said yesterday. Last month, the country’s foreign exchange reserves rose US$5.51 billion from a month earlier to reach US$602.94 billion due to an increase in returns from the central bank’s portfolio management, the movement of other foreign currencies in the portfolio against the US dollar and the bank’s efforts to smooth the volatility of the New Taiwan dollar. Department of Foreign Exchange Director-General Eugene Tsai (蔡炯民)said a rate cut cycle launched by the US Federal Reserve
Handset camera lens maker Largan Precision Co (大立光) on Sunday reported a 6.71 percent year-on-year decline in revenue for the third quarter, despite revenue last month hitting the highest level in 11 months. Third-quarter revenue was NT$17.68 billion (US$581.2 million), compared with NT$18.95 billion a year earlier, the company said in a statement. The figure was in line with Yuanta Securities Investment Consulting Co’s (元大投顧) forecast of NT$17.9 billion, but missed the market consensus estimate of NT$18.97 billion. The third-quarter revenue was a 51.44 percent increase from NT$11.67 billion in the second quarter, as the quarter is usually the peak
The US government on Wednesday sanctioned more than two dozen companies in China, Turkey and the United Arab Emirates, including offshoots of a US chip firm, accusing the businesses of providing illicit support to Iran’s military or proxies. The US Department of Commerce included two subsidiaries of US-based chip distributor Arrow Electronics Inc (艾睿電子) on its so-called entity list published on the federal register for facilitating purchases by Iran’s proxies of US tech. Arrow spokesman John Hourigan said that the subsidiaries have been operating in full compliance with US export control regulations and his company is discussing with the US Bureau of
Pegatron Corp (和碩), a key assembler of Apple Inc’s iPhones, on Thursday reported a 12.3 percent year-on-year decline in revenue for last quarter to NT$257.86 billion (US$8.44 billion), but it expects revenue to improve in the second half on traditional holiday demand. The fourth quarter is usually the peak season for its communications products, a company official said on condition of anonymity. As Apple released its new iPhone 17 series early last month, sales in the communications segment rose sequentially last month, the official said. Shipments to Apple have been stable and in line with earlier expectations, they said. Pegatron shipped 2.4 million notebook
RSS